Valsartan Sacubitril: Has our PARADIGM shifted?
Richard Henry P. Tiongco
Janice Wong Yii Ching
Doreen Su-Yin Tan
Patients with heart failure with preserved ejection fraction (HFpEF) suffer from poor survival, high hospitalisations rate and long-term mortality. HFpEF patients are often overlooked as compared to the more well-known HFrEF where the famous “fantastic four” are now well-known as disease-modifying therapies.The plethora of evidence-based studies have time and again proven their value in the modification of the untoward out comes in the latter.
A recent ARNI trial has shown potential benefits of valsartan sacubitril on patients with HFpEF. Does that change the paradigm of how HFpEF should now be treated? Let us explore how we could apply the trial findings into our real-world clinical practice.
This webinar is the fourth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Janice Wong (Malaysia) and Doreen Tan (Singapore), it includes a speaker presentation from Giuseppe Rosano (UK) and a discussion from panellists Richard Henry Tiongco (Philippines) and Rungroj Krittayphong (Thailand) that will examine the potential use of this agent in HFpEF population, through consideration of real-world examples, live discussions and audience Q&A.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP). The ISCP has been provided support to develop this webinar by Novartis Singapore through an unrestricted educational grant. The supporter has had no influence on the content of the programme or provided any funding to Radcliffe Cardiology.
12.00-13:00 CEST / 18.00-19.00 SGT & PHT
Lecture “Valsartan Sacubitril: Has our PARADIGM shifted?” - Prof Giuseppe Rosano
Presentation – Case 1, followed by panel discussion
Presentation – Case 2, followed by panel discussion
Q&A with live audience - All Faculty
Key Learning Objectives
- To evaluate and understand which patients should and should not be prescribed valsartan sacubitril and which patients groups might benefit most;
- To determine how valsartan sacubitril should be administered and what dosage adjustments and drug interactions need to be noted;
- To analyse special and regional issues that impact the use of this drug;
- To apply evidence-based recommendations to two real world cases.
- Cardiovascular team members - doctors, nurses, pharmacists
- Family physicians
- Cardiovascular pharmacotherapy researchers
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London where he is also the director of MSc Heart Failure.
After obtaining his MD in Medicine and Surgery at the La Sapienza University of Rome, Prof Rosano obtained his specialisation in cardiology from the same University before attaining his PhD in Medical Sciences from Imperial College London. His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases.
Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer-reviewed articles, eight books and 32 book chapters.
Dr Giuseppe Rosano is Deputy Editor-in-Chief of Cardiac Failure Review.
Richard Henry P. Tiongco
Dr Tiongco is currently a Director at the Philippine Heart Association (PHA), was Chair in the past for two Councils (Cardiac Catheterization and Intervention), and was immediate past chair for the council of cardiovascular pharmacotherapy. Dr. Tiongco is currently an Associate Professor at the University of the Philippines in Manila. He is also the Director heading the PHA Bureau of Cardiovascular Disease Control in line for advocacy. Dr Tiongco is likewise the Head for the Philippine College of Physicians Subcommittee on Health and Lifestyle subcommittee for Advocacy. Affiliations/Memberships:
- Associate Professor- 7 : UP College of Medicine, Department of Pharmacology & Toxicology
- Clinical Associate Professor- UP-PGH Division of Cardiology
- Assistant Chair for Administration: UPPGH Cardiology
- Head for Cardiology Fellowship Training in Research
- BLS/ACLS Program Director: UP-PGH Dept. of Internal Medicine (2009 to date)
- Consultant: UP-PGH, Medical Center Manila, St. Luke’s Medical Center Global City,
- Manila Doctor’s Hospital, Asian Hospital & Medical Center
Professor Rungroj Krittayaphong, MD, FESC, FACC is a professor of medicine and Head of the Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University in Bangkok, Thailand. Professor Rungroj received his medical degree from Chulalongkorn University in Bangkok, Thailand in 1987 and subsequently completed cardiology training at Siriraj Hospital. He joined visiting cardiology fellowship at the University of North Carolina, USA from 1993 to 1995, and in cardiac electrophysiology at the University of Southern California, USA in 1996.
Professor Rungroj’s research interests include cardiac MRI, atrial fibrillation, ventricular arrhythmia, radiofrequency ablation and heart rate variability. He is currently the President of the Heart Association of Thailand and President Elect of the ASEAN Federation of Cardiology. He has authored more than 200 articles in peer-reviewed journals including JACC, European Heart Journal and Circulation.
Janice Wong Yii Ching
Miss Wong is clinical pharmacist and Head of Pharmacotherapy Unit in Sarawak Heart Centre, Malaysia. She received her pharmacy degree from International Medical University in Malaysia in 2010 and obtained her master degree in clinical pharmacy from University of Science, Malaysia in 2019.
Doreen Su-Yin Tan
Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore.
Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore. Visiting Cardiology Specialist Pharmacist, National University Hospital Heart Centre, Singapore (NUHCS); Faculty Advisor, NUS Pharmacy Dept Pre-Employment Clinical Training (PECT); Co-Lead, Student-led Collaborative, InnovativePharmacy Inquiry (SCI-PhI) Project, NUS Pharmacy Department; Preceptor, R2 Cardiology Residency Pharmacy Residency Program, Ministry of Health Singapore; Lead,
National Metrics Drug-Related Problems and Productivity committee, Chief PharmacistOffice, Ministry of Health, Singapore; Board of Directors & Singapore Governor,International Society of Cardiovascular Pharmacotherapy; Workgroup Lead for Education (Pharmacy), NUHS Pre-Emptive Pharmacogenomics Steering Committee.
For further information please review her biography in full here: https://pharmacy.nus.edu.sg/team/a-prof-doreen-tan-su-yin/